Discussion on the Treatment Strategy for Stage ⅡA1 Cervical Cancer (FIGO 2018)
ObjectiveThis study aimed to explore the best treatment strategy for International Federation of Gynecology and Obstetrics (FIGO) 2018 stage IIA1 cervical cancer patients by comparing the survival outcomes of two treatment methods: abdominal radical hysterectomy (ARH) with standard postoperative the...
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-04-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2022.800049/full |
| _version_ | 1811309790790418432 |
|---|---|
| author | Xiaolin Chen Wentong Liang Hui Duan Minling Wu Xuemei Zhan Encheng Dai Qiubo Lv Qinghuang Xie Ruilei Liu Yan Xu Xiaonong Bin Jinghe Lang Ping Liu Chunlin Chen |
| author_facet | Xiaolin Chen Wentong Liang Hui Duan Minling Wu Xuemei Zhan Encheng Dai Qiubo Lv Qinghuang Xie Ruilei Liu Yan Xu Xiaonong Bin Jinghe Lang Ping Liu Chunlin Chen |
| author_sort | Xiaolin Chen |
| collection | DOAJ |
| description | ObjectiveThis study aimed to explore the best treatment strategy for International Federation of Gynecology and Obstetrics (FIGO) 2018 stage IIA1 cervical cancer patients by comparing the survival outcomes of two treatment methods: abdominal radical hysterectomy (ARH) with standard postoperative therapy and radio-chemotherapy (R-CT).MethodsPatients with FIGO2018 stage IIA1 cervical cancer who underwent ARH or received R-CT were screened from the clinical diagnosis and treatment for cervical cancer in China (Four C) database. The recurrence cases between the two groups were analyzed. The 5-year overall survival (OS) and disease-free survival (DFS) of patients diagnosed with stage IIA1 cervical cancer in 47 hospitals in mainland China between 2004 and 2018 were compared by using propensity score matching (PSM).ResultsA total of 724 patients met the inclusion criteria. In the total study population, The R-CT group had higher recurrence (22.8% for the R-CT group and 11.2% for the ARH group, P<0.001) rates compared to the ARH group.The 5-year OS and DFS of the ARH group (n=658) were significantly higher than those of the R-CT group (n=66) (OS: 85.9% vs. 71.2%, P=0.009; DFS: 79.2%vs. 70.5%, P=0.027). R-CT was associated with worse 5-year OS (HR=3.19, 95% CI: 1.592-6.956, P=0.001) and DFS (HR=2.089, 95% CI: 1.194-3.656, P=0.01). After 1:2 PSM, the 5-year OS and DFS of the ARH group (n=126) were significantly higher than those of the R-CT group (n=64) (OS:88.9% vs. 70.1%, P=0.04; DFS:82.8% vs. 69.8%, P=0.019). R-CT was still associated with worse 5-year OS (HR=2.391, 95% CI: 1.051-5.633, P=0.046) and DFS (HR=2.6, 95% CI: 1.25-5.409, P=0.011).ConclusionOur study demonstrated that for stage FIGO2018 stage IIA1 cervical cancer patients, ARH offers better oncological outcomes than R-CT. |
| first_indexed | 2024-04-13T09:47:14Z |
| format | Article |
| id | doaj.art-296a9d7a8d384e5e91c1adea6a6fc715 |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-04-13T09:47:14Z |
| publishDate | 2022-04-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-296a9d7a8d384e5e91c1adea6a6fc7152022-12-22T02:51:42ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2022-04-011210.3389/fonc.2022.800049800049Discussion on the Treatment Strategy for Stage ⅡA1 Cervical Cancer (FIGO 2018)Xiaolin Chen0Wentong Liang1Hui Duan2Minling Wu3Xuemei Zhan4Encheng Dai5Qiubo Lv6Qinghuang Xie7Ruilei Liu8Yan Xu9Xiaonong Bin10Jinghe Lang11Ping Liu12Chunlin Chen13Department of Obstetrics and Gynecology, Nanfang Hospital, Southern Medical University, Guangzhou, ChinaDepartment of Obstetrics and Gynecology, Guizhou Provincial People’s Hospital, Guizhou, ChinaDepartment of Obstetrics and Gynecology, Nanfang Hospital, Southern Medical University, Guangzhou, ChinaDepartment of Obstetrics and Gynecology, Nanfang Hospital, Southern Medical University, Guangzhou, ChinaDepartment of Obstetrics and Gynecology, Jiangmen Central Hospital, Jiangmen, ChinaDepartment of Obstetrics and Gynecology, Linyi People’s Hospital, Linyi, ChinaDepartment of Obstetrics and Gynecology, Beijing Hospital, Beijing, ChinaDepartment of Gynecology, Foshan Maternal and Child Health Hospital, Foshan, ChinaDepartment of Obstetrics and Gynecology, Linyi People’s Hospital, Linyi, ChinaDepartment of Obstetrics and Gynecology, Pan Yu Central Hospital, Guangzhou, ChinaDepartment of Epidemiology, College of Public Health, Guangzhou Medical University, Guangzhou, ChinaDepartment of Obstetrics and Gynecology, Peking Union Medical College Hospital, Peking Union Medical College, Beijing, ChinaDepartment of Obstetrics and Gynecology, Nanfang Hospital, Southern Medical University, Guangzhou, ChinaDepartment of Obstetrics and Gynecology, Nanfang Hospital, Southern Medical University, Guangzhou, ChinaObjectiveThis study aimed to explore the best treatment strategy for International Federation of Gynecology and Obstetrics (FIGO) 2018 stage IIA1 cervical cancer patients by comparing the survival outcomes of two treatment methods: abdominal radical hysterectomy (ARH) with standard postoperative therapy and radio-chemotherapy (R-CT).MethodsPatients with FIGO2018 stage IIA1 cervical cancer who underwent ARH or received R-CT were screened from the clinical diagnosis and treatment for cervical cancer in China (Four C) database. The recurrence cases between the two groups were analyzed. The 5-year overall survival (OS) and disease-free survival (DFS) of patients diagnosed with stage IIA1 cervical cancer in 47 hospitals in mainland China between 2004 and 2018 were compared by using propensity score matching (PSM).ResultsA total of 724 patients met the inclusion criteria. In the total study population, The R-CT group had higher recurrence (22.8% for the R-CT group and 11.2% for the ARH group, P<0.001) rates compared to the ARH group.The 5-year OS and DFS of the ARH group (n=658) were significantly higher than those of the R-CT group (n=66) (OS: 85.9% vs. 71.2%, P=0.009; DFS: 79.2%vs. 70.5%, P=0.027). R-CT was associated with worse 5-year OS (HR=3.19, 95% CI: 1.592-6.956, P=0.001) and DFS (HR=2.089, 95% CI: 1.194-3.656, P=0.01). After 1:2 PSM, the 5-year OS and DFS of the ARH group (n=126) were significantly higher than those of the R-CT group (n=64) (OS:88.9% vs. 70.1%, P=0.04; DFS:82.8% vs. 69.8%, P=0.019). R-CT was still associated with worse 5-year OS (HR=2.391, 95% CI: 1.051-5.633, P=0.046) and DFS (HR=2.6, 95% CI: 1.25-5.409, P=0.011).ConclusionOur study demonstrated that for stage FIGO2018 stage IIA1 cervical cancer patients, ARH offers better oncological outcomes than R-CT.https://www.frontiersin.org/articles/10.3389/fonc.2022.800049/fullcervical cancerstage ⅡA1overall survivaldisease-free survivaltreatment strategies |
| spellingShingle | Xiaolin Chen Wentong Liang Hui Duan Minling Wu Xuemei Zhan Encheng Dai Qiubo Lv Qinghuang Xie Ruilei Liu Yan Xu Xiaonong Bin Jinghe Lang Ping Liu Chunlin Chen Discussion on the Treatment Strategy for Stage ⅡA1 Cervical Cancer (FIGO 2018) Frontiers in Oncology cervical cancer stage ⅡA1 overall survival disease-free survival treatment strategies |
| title | Discussion on the Treatment Strategy for Stage ⅡA1 Cervical Cancer (FIGO 2018) |
| title_full | Discussion on the Treatment Strategy for Stage ⅡA1 Cervical Cancer (FIGO 2018) |
| title_fullStr | Discussion on the Treatment Strategy for Stage ⅡA1 Cervical Cancer (FIGO 2018) |
| title_full_unstemmed | Discussion on the Treatment Strategy for Stage ⅡA1 Cervical Cancer (FIGO 2018) |
| title_short | Discussion on the Treatment Strategy for Stage ⅡA1 Cervical Cancer (FIGO 2018) |
| title_sort | discussion on the treatment strategy for stage iia1 cervical cancer figo 2018 |
| topic | cervical cancer stage ⅡA1 overall survival disease-free survival treatment strategies |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2022.800049/full |
| work_keys_str_mv | AT xiaolinchen discussiononthetreatmentstrategyforstageiia1cervicalcancerfigo2018 AT wentongliang discussiononthetreatmentstrategyforstageiia1cervicalcancerfigo2018 AT huiduan discussiononthetreatmentstrategyforstageiia1cervicalcancerfigo2018 AT minlingwu discussiononthetreatmentstrategyforstageiia1cervicalcancerfigo2018 AT xuemeizhan discussiononthetreatmentstrategyforstageiia1cervicalcancerfigo2018 AT enchengdai discussiononthetreatmentstrategyforstageiia1cervicalcancerfigo2018 AT qiubolv discussiononthetreatmentstrategyforstageiia1cervicalcancerfigo2018 AT qinghuangxie discussiononthetreatmentstrategyforstageiia1cervicalcancerfigo2018 AT ruileiliu discussiononthetreatmentstrategyforstageiia1cervicalcancerfigo2018 AT yanxu discussiononthetreatmentstrategyforstageiia1cervicalcancerfigo2018 AT xiaonongbin discussiononthetreatmentstrategyforstageiia1cervicalcancerfigo2018 AT jinghelang discussiononthetreatmentstrategyforstageiia1cervicalcancerfigo2018 AT pingliu discussiononthetreatmentstrategyforstageiia1cervicalcancerfigo2018 AT chunlinchen discussiononthetreatmentstrategyforstageiia1cervicalcancerfigo2018 |